Evidence map›Paper›PMID 34888479›Full record

ArticleAccess microbiology2021

Success of ceftazidime-avibactam and aztreonam in combination for a refractory biliary infection with recurrent bacteraemia due to

Genevieve McKew, John Merlino, Alicia Beukers, Sebastian van Hal, Thomas Gottlieb

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Access microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Genevieve McKewDepartment of Microbiology and Infectious Diseases, NSW Pathology, Concord Repatriation General Hospital, Concord, NSW, Australia.ORCID https://orcid.org/0000-0002-5238-9260
John MerlinoDepartment of Microbiology and Infectious Diseases, NSW Pathology, Concord Repatriation General Hospital, Concord, NSW, Australia.
Alicia BeukersFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Sebastian van HalFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Thomas GottliebDepartment of Microbiology and Infectious Diseases, NSW Pathology, Concord Repatriation General Hospital, Concord, NSW, Australia.ORCID https://orcid.org/0000-0002-7856-5517
The University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfections due to metallo-beta-lactamase (MBL)-producing organisms are becoming a significant problem, and antibiotic treatment options are limited. Aztreonam inhibits MBLs, and its use in combination with ceftazidime-avibactam (CAZ-AVI-AZT) to inhibit other beta-lactamases shows promise.

methodsA 45-year-old woman suffered from recurrent and sustained MBL (

resultsA layered Etest method for synergy between CAZ-AVI and aztreonam demonstrated an MIC of 2 mg l

conclusionWhile aztreonam inhibits MBLs, MBL-positive isolates often express other beta-lactamase enzymes. Avibactam inhibits ESBLs and other beta-lactamases, and its use in this case possibly contributed to therapeutic success due to inhibition of the concomitant

Indexed as

aztreonamblaIMP-4carbapenemaseceftazidime–avibactamEnterobacter hormaechei subsp. oharae

Identifiers

PMID34888479
PMCPMC8650849
OpenAlexW3191196369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.